Bioventure, a subsidiary of GlobalOne Healthcare Holding within Yas Holding’s healthcare division, has partnered with Amman Pharmaceutical Industries, a leading pharmaceutical manufacturer with operations across the MENA region and other markets, to bring Aflibercept, a biosimilar of Bayer’s Eylea, to patients in the Levant region. The partnership grants Amman Pharma exclusive rights to register, hold marketing authorisation, and commercialise Aflibercept, which is developed and manufactured by Iceland-based biopharmaceutical company Alvotech, and indicated for neovascular (Wet) age-related macular degeneration, diabetic macular edema, and other serious eye conditions.
Dr. Fadi Alatrash, General Manager of Amman Pharmaceutical Industries, stated, “We are proud to collaborate with Bioventure, a world-leading biopharmaceutical company, to market and commercialise Aflibercept. This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region. It also expands our biosimilar portfolio and strengthens our position in the niche Ophthalmology market.”
This exclusive license agreement marks a significant step forward for both Bioventure and Amman Pharmaceuticals Industries, as they strive to bring innovative, quality healthcare solutions to patients in the Levant region.
“At GlobalOne Healthcare, we are dedicated to making medicine more accessible and improving patient outcomes. Our partnership with Amman Pharmaceutical Industries to bring Aflibercept to the Levant region is a testament to this commitment. I am confident that this collaboration will bring significant value to patients in need and further solidify our position as a leader in the pharmaceutical and healthcare industries.” – Ashraf Radwan, CEO of GlobalOne Healthcare commented.